TNL Mediagene filed a Form 6-K on November 18, 2026, disclosing that it received a letter from Nasdaq on November 16, 2026, confirming the company regained compliance with Nasdaq Listing Rule 5550(b)(1) and is in full compliance with the terms of the Nasdaq Hearings Panel's August 23, 2026 decision.

Key Highlights

  • Compliance confirmed: Nasdaq notified TNL Mediagene on November 16, 2026 that it had regained compliance with the Equity Rule (Listing Rule 5550(b)(1)).
  • Panel decision satisfied: The company is described as "in full compliance with the terms set forth in the Panel's decision letter dated August 23, 2026."
  • Mandatory Panel Monitor imposed: Pursuant to Listing Rule 5815(d)(4)(B), the company is subject to a one-year Mandatory Panel Monitor beginning from the date of the November 16, 2026 letter.
  • Restricted cure rights during monitoring: If the company falls out of compliance with the Equity Rule during the monitoring period, it will not be permitted to submit a compliance plan or receive additional time to regain compliance.
  • Delist risk during monitoring: A further violation during the monitoring year would trigger a Delist Determination Letter, with the company's recourse limited to requesting a new hearing before the Hearings Panel.
  • Exchange listing: The filing identifies TNL Mediagene as listed on The Nasdaq Capital Market, Commission File Number 001-42424.

TNL Mediagene's Path Back to Nasdaq Equity Compliance and Ongoing Monitoring Terms

According to the filing, TNL Mediagene had previously been granted continued listing on The Nasdaq Capital Market following a request to the Nasdaq Hearings Panel. That grant, communicated in a Panel letter dated August 23, 2026, was conditional on the company demonstrating compliance with Listing Rule 5550(b)(1), the Equity Rule, on or before October 30, 2026. The company disclosed it had furnished the SEC with a Form 6-K on August 25, 2026 describing those original conditions.

The November 16, 2026 letter from Nasdaq, as described in this filing, confirms that TNL Mediagene satisfied those conditions and is now in full compliance. However, the filing also discloses that the company is subject to a Mandatory Panel Monitor for one year from the date of that letter, as required under Listing Rule 5815(d)(4)(B). During this monitoring period, if the Nasdaq Listing Qualifications Department determines the company is again out of compliance with the Equity Rule, the company "will not be permitted to provide the Staff with a plan of compliance with respect to that deficiency," and no additional time or cure period will be granted under Listing Rules 5810(c)(2) or 5810(c)(3).

The filing further states that under such a scenario, the Staff would issue a Delist Determination Letter, and the company's available remedy would be to request a new hearing before the initial Panel or a newly convened Hearings Panel, as provided by Listing Rule 5815(d)(4)(C). The report was signed by Tae Jun Park, General Counsel and Chief Corporate Affairs Officer of TNL Mediagene, and a press release dated November 18, 2026 was furnished as Exhibit 99.1.

What Was Disclosed

TNL Mediagene disclosed via Form 6-K that Nasdaq confirmed on November 16, 2026 the company regained compliance with the Equity Rule and satisfied prior Panel conditions, while also notifying the company it will be subject to a one-year Mandatory Panel Monitor with restricted compliance remedies.